Opimont-L Tablet
Images are for reference. Actual packaging may vary.
Levocetirizine (5mg) + Montelukast (10mg)
Strip of 10 tablets • Tablet
A valid prescription is required for this medicine.
Haven’t found an alternative? A health advisor can help you understand what to do next.
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
+1 more active ingredient
Levocetirizine selectively antagonizes H1 histamine receptors, inhibiting the effects of histamine in allergic responses.
Montelukast selectively antagonizes leukotriene receptors, inhibiting their effects on bronchoconstriction and inflammation.
Medical applications
Opimont-L Tablet contains Levocetirizine 5mg and Montelukast 10mg, a combination therapy indicated for the management of allergic rhinitis and asthma. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, nasal congestion, runny nose, and itching associated with allergic conditions.
Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema. The synergistic effect of these two agents provides comprehensive relief from both upper and lower respiratory allergic manifestations. Opimont-L is particularly beneficial for patients requiring control of seasonal or perennial allergic rhinitis concomitant with asthma or exercise-induced bronchospasm.
The recommended dosage is one tablet once daily, preferably in the evening, to optimize symptom control over a 24-hour period. Caution is advised in patients with hepatic impairment, and the drug should be used under medical supervision in pediatric and elderly populations. Common adverse effects include headache, fatigue, dry mouth, and gastrointestinal disturbances, which are generally mild and transient.
Opimont-L Tablet should be prescribed following a thorough clinical evaluation to ensure suitability and monitor therapeutic response.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Safety information not available for this product. Please consult your doctor or pharmacist.
0 reviews for Opimont-L Tablet







